Literature DB >> 8161718

Dose dependent absorption and linear disposition of cyclosporin A in rat.

A Lindberg-Freijs1, M O Karlsson.   

Abstract

The pharmacokinetics of cyclosporin A (CyA) were investigated in the rat following intravenous doses of 1.7, 3.3, and 6.4 mg kg-1 and oral doses of 3.1, 6.8, and 12.9 mg kg-1. The blood concentration-time profile after intravenous administration was adequately described by a two-compartment model when all data were simultaneously analysed using NONMEM. The disposition pharmacokinetics were linear over the dose range studied; the average total blood clearance was 0.19 l g-1 kg-1. The absorption process could not be adequately described by either a first- or a zero-order input. Therefore, a flexible, staircase input model was used and found to be superior to the standard models. The shape of this model was biphasic, with a higher initial input rate than expected from first-order absorption. The duration of this first phase increased with dose. The extent of absorption was also dose dependent. Bioavailability was higher at higher doses; the values were 45%, 67% and 76% for the three ascending dose levels. These results strongly indicate a saturable first-pass effect. Since the extraction of CyA in the liver is only 6%, the marked increase in bioavailability of CyA is most likely to be the result of saturated gut wall metabolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161718     DOI: 10.1002/bdd.2510150107

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

Authors:  Josef A Vogt; Christian Denzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-02       Impact factor: 2.745

3.  Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.

Authors:  Iñaki F Trocóniz; Jan-Markus Wolters; Christiane Tillmann; Hans G Schaefer; Willy Roth
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed.

Authors:  Timothy A Hill; Rink-Jan Lohman; Huy N Hoang; Daniel S Nielsen; Conor C G Scully; W Mei Kok; Ligong Liu; Andrew J Lucke; Martin J Stoermer; Christina I Schroeder; Stephanie Chaousis; Barbara Colless; Paul V Bernhardt; David J Edmonds; David A Griffith; Charles J Rotter; Roger B Ruggeri; David A Price; Spiros Liras; David J Craik; David P Fairlie
Journal:  ACS Med Chem Lett       Date:  2014-08-04       Impact factor: 4.345

5.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

7.  Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Authors:  Nikolaos Tsamandouras; Thierry Wendling; Amin Rostami-Hodjegan; Aleksandra Galetin; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-05-26       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.